Copyright
©The Author(s) 2024.
World J Hepatol. May 27, 2024; 16(5): 716-730
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.716
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.716
Advantages | Disadvantages | |
AFP testing | Widely used; relatively cost-effective | Limited sensitivity, especially in early-stage HCC; prone to false positives/negatives |
Genomic profiling (next-Generation sequencing, whole-genome sequencing) | High sensitivity for detecting genetic alterations; provides comprehensive genomic information | Costly; complex data analysis; may identify variants of uncertain significance |
Liquid biopsy (circulating tumor DNA) | Non-invasive; potential for early detection; provides real-time monitoring | Limited sensitivity in early stages; technical challenges; standardization concerns |
Imaging techniques (MRI, CT, ultrasound) | Commonly used; assesses tumor characteristics and location | Limited sensitivity for small lesions; exposure to radiation (CT); may not detect molecular changes |
Molecular biomarkers (miRNA, methylation patterns) | High specificity; potential for early detection | Variable sensitivity; limited standardization; assay complexity |
Circulating tumor cells analysis | May reflect metastatic potential; potential for real-time monitoring | Rare in early stages; technical challenges; standardization issues |
- Citation: Peruhova M, Banova-Chakarova S, Miteva DG, Velikova T. Genetic screening of liver cancer: State of the art. World J Hepatol 2024; 16(5): 716-730
- URL: https://www.wjgnet.com/1948-5182/full/v16/i5/716.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i5.716